Piper Sandler Maintains Overweight on PROCEPT BioRobotics, Lowers Price Target to $25

Benzinga Newsdesk www.benzinga.com Negative 87.8%

Neg 87.8% Neu 0% Pos 0%

Piper Sandler analyst Matt O'Brien maintains PROCEPT BioRobotics (NASDAQ:PRCT) with a Overweight and lowers the price target from $35 to $25.